Postępy Dermatologii i Alergologii

Full text

5/2026 vol. 43
Review paper

Subclinical atherosclerosis in psoriasis: an integrated systematic review of vascular imaging, circulating biomarkers and effects of systemic therapy

Soliman Ayed Alsaiari 1
,
Alhassan Abdullah B. Almakrami 2
,
Yazeed Khalid A. Moafa 2
,
Hashan Fahad H. Alyami 2
,
Abdullah Ghazy M. Alosaimi 2
,
Saleh Abdullah S. Al Gharzan 2
,
Ibrahim Ali B. Sarrar 2
,
Salem Mohammed S. Alyami 2
,
Abdulaziz Salaiman M. Alsaiari 2
,
Mohammed Ali M. Alqarni 2

  1. College of Medicine, Najran University, Najran, Saudi Arabia

  2. Medical intern, Najran University, Najran City, Najran, Saudi Arabia

Adv Dermatol Allergol 2026; XLIII (5): 480-489

DOI: https://doi.org/10.5114/ada.2026.165950
Data publikacji online: 2026/10/22
Article file
Subclinical atherosclerosis - Alsaiari.pdf
  1. Parisi R, Iskandar IY, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ 2020; 369: m1590.
  2. Griffiths CE, Armstrong AW, Gudjonsson JE. Barker JNWN. Psoriasis. Lancet 2021; 397: 1301-5.
  3. Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol 2017; 140: 645-53.
  4. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-41.
  5. Ahlehoff O, Gislason GH, Charlot M, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med 2011; 270: 147-57.
  6. Boehncke WH, Boehncke S, Tobin AM, Kirby B. The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 2011; 20: 303-7.
  7. Ji E, Lee S. Antibody-based therapeutics for atherosclerosis and cardiovascular diseases. Int J Mol Sci 2021; 22: 5770.
  8. Talepoor AG, Fouladseresht H, Khosropanah S, Doroudchi M. Immune-inflammation in atherosclerosis: a new twist in an old tale. Endocr Metab Immune Disord Drug Targets 2020; 20: 525-45.
  9. Lorenz MW, Markus HS, Bots ML, et al. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007; 115: 459-67.
  10. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71.
  11. Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
  12. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25: 603-5.
  13. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.
  14. Bia³ecka A, Bia³ecki M, Serafin Z, Czajkowski R. Atherosclerosis attacks in patients with psoriasis vulgaris but without a relationship with the severity and course of the disease. Adv Dermatol Allergol 2021; 38: 673-81.
  15. Berna-Rico E, de Aragon CA, Ballester-Martinez A, et al. Monocyte-to-high-density lipoprotein ratio is associated with systemic inflammation, insulin resistance, and coronary subclinical atherosclerosis in psoriasis: results from 2 observational cohorts. J Investig Dermatol 2024; 144: 2002-12.
  16. Asami M, Ototake Y, Takamura N, et al. Abnormal inflammatory traits and downregulated caveolin-1 expression in monocytes of psoriasis patients may be associated with psoriatic inflammation and atherosclerosis. J Dermatol Sci 2022; 107: 65-74.
  17. Kaiser H, Wang X, Kvist-Hansen A, et al. Biomarkers of subclinical atherosclerosis in patients with psoriasis. Sci Rep 2021; 11: 21438.
  18. Patel NH, Osborne MT, Teague H, et al. Heightened splenic and bone marrow uptake of 18F-FDG PET/CT is associated with systemic inflammation and subclinical atherosclerosis by CCTA in psoriasis: an observational study. Atherosclerosis 2021; 339: 20-6.
  19. Gonzalez-Cantero A, Teklu M, Sorokin AV, et al. Subclinical liver disease is associated with subclinical atherosclerosis in psoriasis: results from two observational studies. J Investig Dermatol 2022; 142: 88-96.
  20. Huong NT, Long B, Doanh LH, et al. Associations of different inflammatory factors with atherosclerosis among patients with psoriasis vulgaris. Front Med 2024; 11: 1396680.
  21. Çelik HH, Kuyumcu MS, Şirin FB, et al. Could SCUBE-1 be a marker for subclinical atherosclerosis other than carotid artery intima-media thickness in patients with psoriasis? An Brasil Dermatol 2023; 98: 595-601.
  22. Mourino-Alvarez L, Perales-Sanchez I, Berna-Rico E, et al. Association of the complement system with subclinical atherosclerosis in psoriasis: findings from an observational cohort study. J Investig Dermatol 2024; 144: 1075-87.
  23. Deoghare S, Talanikar H, Deora MS, et al. A cross-sectional study to assess sub-clinical atherosclerosis in patients of psoriasis independent of metabolic syndrome. Indian J Dermatol 2022; 67: 328-33.
  24. Neema S, Vasudevan B, Misra P, et al. Treating adult patients of severe psoriasis with methotrexate leads to reduction in biomarkers of atherosclerosis: a prospective study. Med J Armed Forces India 2024; 80: S174-9.
  25. Tsiogka A, Soulaidopoulos S, Gregoriou S, et al. Effects of IL17/23 inhibitors on markers of subclinical atherosclerosis in patients with psoriasis: an observational study. Dermatol Ther 2025; 15: 3777-92.
  26. Salecha AJ, Bellamkonda SK, Samanthula H, Jakkampudi A. Ultrasonographic evaluation of subclinical atherosclerosis in the femoral and carotid arteries of patients with psoriasis. Iran J Dermatol 2022; 25: 309-14.
  27. Awan S, Kiyani A, Aman PF, et al. Frequency of subclinical atherosclerosis in patients of psoriasis. Pakistan Armed Forces Med J 2022; 72: S683.
  28. Gaballah MA, Eldegla SI, Taman SE, Salem HA. Platelet mass index as early indicator of subclinical atherosclerosis in psoriasis: a case–control study. J Egypt Women’s Dermatol Soc 2022; 19: 81-7.
  29. Taş-Aygar G, Çevirgen-Cemil B, Kaplanoğlu H, et al. Is sortilin an indicator of subclinical atherosclerosis in patients with psoriasis? J Clin Pract Res 2024; 46: 259-65.
  30. Pietrzak A, Bartosiñska J, Chodorowska G, et al. Cardiovascular aspects of psoriasis: an updated review. Int J Dermatol 2013; 52: 153-62.
  31. Naik HB, Natarajan B, Stansky E, et al. Severity of psoriasis associates with aortic vascular inflammation detected by FDG PET/CT and neutrophil activation in a prospective observational study. Arterioscler Thromb Vasc Biol 2015; 35: 2667-76.
  32. Mehta NN, Li R, Krishnamoorthy P, et al. Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis. Atherosclerosis 2012; 224: 218-21.
  33. Madhur MS, Funt SA, Li L, et al. Role of interleukin 17 in inflammation, atherosclerosis, and vascular function in apolipoprotein E–deficient mice. Arterioscler Thromb Vasc Biol 2011; 31: 1565-72.
  34. Bhole D, Stahl GL. Molecular basis for complement component 6 (C6) deficiency in rats and mice. Immunobiology 2004; 209: 559-68.
  35. Boehncke WH, Boehncke S, Tobin AM, Kirby B. The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 2011; 20: 303-7.
  36. von Stebut E, Reich K, Thaçi D, et al. Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks. J Investig Dermatol 2019; 139: 1054-62.
  37. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-41.
  38. Fang N, Jiang M, Fan Y. Association between psoriasis and subclinical atherosclerosis: a meta-analysis. Medicine 2016; 95: e3576.
  39. Yousefi M, Shakeri P, Tahvildari A, et al. Exploring the association between psoriasis and subclinical atherosclerosis defined by carotid intima-media thickness (CIMT) in patients with psoriasis vulgaris: a systematic review and meta-analysis. Ir J Med Sci 2025; 194: 475-89.
  40. Wu H, Luo Z, Liu J, et al. Association between psoriasis and coronary artery calcification: a systematic review and meta-analysis. Front Cardiovasc Med 2022; 9: 1044117.
  41. Martinez-Moreno A, Ocampo-Candiani J, Garza-Rodriguez V. Psoriasis and cardiovascular disease: a narrative review. Korean J Fam Med 2021; 42: 345-55.
  42. Kaiser H, Näslund-Koch C, Kvist-Hansen A, Skov L. Does systemic anti-psoriatic treatment impact the risk of cardiovascular disease? A review over cardiovascular imaging studies. Dermatol Ther 2024; 14: 303-21.
  43. González-Cantero A, Ortega-Quijano D, Álvarez-Díaz N, et al. Impact of biological agents on imaging and biomarkers of cardiovascular disease in patients with psoriasis: a systematic review and meta-analysis of randomized placebo-controlled trials. J Invest Dermatol 2021; 141: 2402-11.
Copyright: © 2026 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
SUBMIT YOUR PAPER
Share
without publication fees
Indexed in
pubmed
Integrated with
integrated with publons
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications